A high pan-immune-inflammation value before chemoradiotherapy indicates poor outcomes in patients with small-cell lung cancer

Conclusion: The findings of this retrospective study indicate that the pretreatment PIV is a reliable and independent prognostic biomarker for patients with LS-SCLC who were treated with C-CRT and PCI.PMID:37404137 | PMC:PMC10331221 | DOI:10.1177/03946320231187759

Source: International Journal of Immunopathology and Pharmacology - July 5, 2023 Category: Allergy & Immunology Authors: Ahmet Kucuk Erkan Topkan Emine Elif Ozkan Duriye Ozturk Berrin Pehlivan Ugur Selek Source Type: research